H.C. Wainwright maintains Buy for EVMN Evommune Inc Feb 10 2026

H.C. Wainwright maintained a Buy rating on Evommune, Inc. (EVMN) on February 10, 2026, and raised its price target to $65. The same day Evercore ISI kept an Outperform rating and raised its target to $55. Both firms left their fundamental ratings intact while lifting valuation markers, signaling continued confidence in Evommune’s prospects despite recent share weakness. This EVMN analyst rating action gives investors two notable price targets to weigh against the company’s $373,910,887 market capitalization and recent performance.